Table 5.

Summary of ongoing clinical trials using FUS technology in GBM patients.

NCT Number/Study Completion Date	Status/Location	FUS Device + Drug	Primary Outcome Measures
NCT03616860 Study Completion Date: December 2024	Recruiting Location: Canada	Device: ExAblate Neuro Model 4000 Type 2 Drug: TMZ	Device and procedure related adverse events (safety)
NCT03551249 Study Completion Date: December 2024	Recruiting Location: US	Device: ExAblate Neuro Model 4000 Type 2 Drug: TMZ	Device and procedure related adverse events (safety)
NCT04440358 Study Completion Date: April 2023	Recruiting Location: Canada	Device: ExAblate Neuro Model 4000 Type 2 Drug: Carboplatin	Adverse events (safety) Contrast intensity on MR imaging
NCT04417088 Study Completion Date: November 2023	Recruiting Location: US	Device: ExAblate Neuro Model 4000 Type 2 Drug: Carboplatin	Adverse events (safety) Contrast intensity on MR imaging
NCT03712293 Study Completion Date: December 2021	Recruiting Location: Korea	Device: ExAblate Neuro Model 4000 Type 2 Drug: TMZ	Adverse events (safety)
NCT04446416 Study Completion Date: December 2022	Recruiting Location: Taiwan	Device: NaviFUS System Drug: BVZ	Adverse events (safety) PFS at 6 months